Cellular reprogramming draws serious capital and reaches its first human dose, a large Phase 3 oral drug delivers near-injectable results, and the circadian-dementia signal hardens.
NewLimit closed a $435M Series C to advance its epigenetic reprogramming platform, which targets partial cell rejuvenation by modifying methylation patterns that regulate gene expression in aged cells without reverting them to a pluripotent state.
Life Biosciences administered ER-100 — a cellular reprogramming injection targeting glaucoma — to its first human participant, marking the first-in-human milestone for direct ocular reprogramming.
Merck's enlicitide Phase 3 trial (n=2,909 high-cardiovascular-risk patients) showed approximately 60% LDL reduction over the primary endpoint period, with a safety profile comparable to existing statins.
A Neurology study by UT Southwestern researchers found individuals with the most fragmented circadian rhythms — irregular sleep-wake timing rather than simply short sleep duration — had more than 2.5x the dementia risk of those with consistent rhythms.
Research presented at DDW 2026 by UT Medical Branch showed that transplanting gut microbiota from young donors reversed markers of liver aging and prevented hepatocellular carcinoma development in aged mouse recipients.
A Nature Aging study using single-nucleus sequencing in primate small intestine identified NCoR1 as a gene regulator whose expression declines significantly with age, and showed that metformin treatment restored NCoR1 activity toward younger-animal levels.
Analysis of 147,000 participants published in the British Journal of Sports Medicine found that 90-120 minutes per week of resistance training was associated with maximum all-cause mortality benefit, with returns diminishing at higher volumes.